New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
July 31, 2014
09:03 EDTBTXBioTime unit expands clinical development of bladder cancer test
BioTime and its subsidiary OncoCyte announced that OncoCyte has expanded the clinical development of its urine-based bladder cancer diagnostic test by initiating a multi-site clinical trial. The trial, which will involve up to 1,200 patient samples obtained from at least four large urology clinics located throughout the U.S., has received Institutional Review Board approval at multiple sites and should begin enrolling patients within the next week. OncoCyte’s initial clinical study of its bladder cancer diagnostic test began in January and involves pathology specimens being collected at a leading medical institution with an international reputation for excellence and discovery. The multi-site clinical trial is designed to expand the potential use of the PanC-Dx bladder cancer test beyond pathology laboratories and into urologic practices at the point of cystoscopy. Cystoscopy along with urine cytopathology, are the standard methods utilized for bladder cancer screening and diagnosis. The multi-site clinical trial should be completed within 12 months. The goal of the current clinical trial is to compare the performance of OncoCyte’s proprietary PanC-Dx bladder cancer markers to the performance of cystoscopy.
News For BTX From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
May 19, 2015
08:04 EDTBTXBioTime says positive interim results of blood-based cancer test to be presented
Subscribe for More Information
May 14, 2015
08:03 EDTBTXBioTime sees OncoCyte funding sufficient for operations into early 2016
BioTime and its subsidiary OncoCyte Corporation announced that OncoCyte has received a new round of financing to fund further development and commercialization activities for its cancer diagnostic products. With completion of the financing, which included a cash investment of $3.3M and conversion of $3.3M of existing debt into equity, OncoCyte has approximately $7M in cash and marketable securities, which should be sufficient to fund current operations into early 2016, the company stated.
May 13, 2015
08:04 EDTBTXBioTime unit awarded $1.6M grand from Israel's OCS
BioTime and its subsidiary Cell Cure Neurosciences announced that Cell Cure has been awarded a grant for 2015 of approximately $1.61M from Israel’s Office of the Chief Scientist to help finance the development of OpRegen, a cell-based therapeutic product that consists of animal product-free retinal pigment epithelial cells with high purity and potency. Cell Cure is now enrolling patients at Hadassah University Medical Center in Jerusalem, Israel, in a clinical Phase I/IIa dose-escalation study evaluating the safety and efficacy of OpRegen for geographic atrophy, the severe stage of the dry form of age-related macular degeneration. The Phase I/IIa clinical trial was opened in February 2015 following regulatory clearance from the U.S. FDA and the Israeli Ministry of Health. The trial consists of four cohorts and will evaluate three different dose regimens. Cell Cure expects to report interim data from the cohorts in the coming months.
May 12, 2015
09:38 EDTBTXBioTime management to meet with Oppenheimer
Meetings to be held in New York on May 14 and in Boston on May 15 hosted by Oppenheimer.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use